

- Polycystic kidney disease, autosomal dominant (Cont.):
 pathogenesis of, 1850–1851, 1851f
 treatment of, 1853
 autosomal recessive, 1850t, **1853**
 Polycystic ovarian syndrome (PCOS)
 in CAH, 2356
 hirsutism in, 331, 332
 infertility in, 2389
 insulin resistance in, 2406
 menstrual disorders in, 337
 metabolic syndrome and, 337, 2452
 obesity and, 415e-6
 prevalence of, 2254t
 screening/testing for, 2254t
 skin manifestations of, 352, 356t, 359
 sleep apnea in, 6e-5
 treatment of, 337
 Polycystin-1/2, 1850, 1851f
 Polycythemia, **399**
 as adaptation to hypoxia, 248
 approach to, 400f
 clinical features of, 399–400
 erythromelalgia in, 1650
 secondary, 249
 smoker's, 400
 spurious, 400
 Polycythemia vera, **672**
 classification of, 672, 672t
 clinical features of, 399, 673
 complications of, 673–674
 vs. cyanosis, 248
 diagnosis of, 400, 673, 673t
 epidemiology of, 672
 etiology of, 672–673
 genetic considerations in, 672–673
 splenomegaly in, 411, 673–674
 treatment of, 674
 Polydipsia
 dipsogenic, 2276, 2279
 etiology of, 295
 hyponatremia in, 301
 iatrogenic, 2276, 2279
 primary, 2276, 2277, 2279
 psychogenic, 2276, 2279
 Polydrug abuse, 469e-5. *See also* Substance use disorders
 Polyethylene glycol, 274, 1970t
 Polygenic disorders, 425, 438t, 440
 Polyglandular autoimmune (PGA) insufficiency, 2366, 2483
 Polyglycolic acid, 92e-1
 Polymerase chain reaction (PCR)
 definition of, 769t
 for genetic testing, 444, 447
 in infectious disease diagnosis, 769t
 in pneumonia diagnosis, 806
 in viral encephalitis diagnosis, 894
 in viral meningitis diagnosis, 891
 Polymer fume fever, 1692
 Polymorphic microsatellite markers, 441
 Polymorphic reticulosis. *See* Extranodal NK/T-cell lymphoma, nasal type
 Polymorphism, 433. *See also* Single-nucleotide polymorphisms (SNPs)
 Polymorphonuclear leukocytes (PMNs), 150e-1, 1601
 Polymorphous light eruption, 364t, 366, 388–389
 Polymyalgia rheumatica, **2188**
 as cause of fever of unknown origin, 138
 clinical features of, 202, 462e-2, 2188, 2199
 definition of, 2188
 diagnosis of, 2189
 treatment of, 141, 2189
 Polymyositis, **2194**
 clinical features of, 157, 2194–2196, 2195t
 diagnosis of, 2199–2200, 2199t, 2200f
 differential diagnosis of, 2197–2199
 dysphagia in, 257
 immunopathology of, 372e-24t, 2196, 2197f
 interstitial lung disease in, 1714
 parasitic, 2198
 prognosis of, 2202f
 Raynaud's phenomenon in, 1649
 treatment of, 2200–2202
 tropical, 2198
 viral infections and, 2197
 Polymyxin B
 for *Acinetobacter* infections, 1037t
 action of, 931t, 933, 934, 944
 adverse effects of, 381, 938t, 944, 1037
 for gram-negative bacterial infection, 1026, 1027
 indications for, 944
 for otitis externa, 228
 resistance to, 931t, 934, 941t
 Polymyxin-bacitracin, 199
 Polymyxin E (colistin)
 for *Acinetobacter* infections, 1037t
 action of, 931t, 933, 934, 944
 adverse effects of, 938t, 944, 1027
 for gram-negative bacterial infection, 1026, 1027
 indications for, 941t, 944
 for *Klebsiella* infections, 1033
 for *P. aeruginosa* infection, 1045t, 1047
 resistance to, 931t, 934
 Polyneuropathy
 acute inflammatory demyelinating, 2695, 2695t, 2696t
 acute toxic, 157
 autoantibodies in, 372e-24t
 chronic inflammatory demyelinating, 2696t, **2698**
 critical illness, 1755, 1783–1784, 2684
 cryptogenic sensory and sensorimotor, 2691
 diabetic. *See* Diabetic neuropathy
 familial amyloid, 2681
 in Guillain-Barré syndrome. *See* Guillain-Barré syndrome (GBS)
 hereditary sensory and autonomic, 2680
 in HIV infection, neurologic disease in
 large-fiber, 161
 in monoclonal gammopathy of undetermined significance, 2700
 in multiple myeloma, 2699–2700
 sensory deficits in, 161
 small-fiber, 161
 weakness in, 157
 Polyomavirus(es). *See also* BK virus infection; JC virus infection
 gene expression and replication in, 214e-4
 Merkel cell, 926
 structure of, 214e-2t, 214e-3f
 in transplant recipient, 926
 Polyp(s)
 colorectal
 bleeding from, 277
 endoscopic findings in, 1881, 1882f, 1883f
 endoscopic treatment of, 346e-1v
 in familial adenomatous polyposis, 1897f. *See also* Familial adenomatous polyposis
 flat serrated, 1881, 1883f
 pathogenesis of cancer in, 537–538. *See also* Colorectal cancer
 gallbladder, 2083
 Polypharmacy, in elderly, 77–78
 Polypill, 266e-6
 Polyploidy, of mitochondrial DNA, 85e-1–2
 Polyposis, juvenile, 101e-6t, 538t
 Polyposis coli. *See* Familial adenomatous polyposis
 Polyradiculopathy
 diabetic. *See* Diabetic neuropathy
 in HIV infection. *See* HIV infection, neurologic disease in
 Polyreactive natural antibodies, 372e-2
 Polysaccharide A, in abscess formation, 849
 Polysaccharide antigens, selective antibody deficiency to, 2112
 Polysaccharide capsule, pneumococcal, 947, 947f
 Polysaccharide iron, for iron-deficiency anemia, 629t
 Polysomnography, 184, 189f
 Polyunsaturated long-chain triglycerides, 98e-4–5
 Polyuria
 approach to the patient, 294, 294f
 hypokalemic, 307
 pathophysiology of, 294–295
 in sepsis/septic shock, 1755
 treatment of, 304
 in urinary tract obstruction, 1872
 in water diuresis, 64e-3
 Pomalidomide, 103e-19, 717
 POMC. *See* Proopiomelanocortin (POMC)
 POMC gene, 401e-1, 401e-4, 611
 POMC gene mutations, 415e-3, 2325t
 Pompe disease (acid α -1,4 glucosidase deficiency)
 clinical features of, 432e-4t, 432e-6, 433e-2t, 433e-4–5, 462e-14
 diagnosis of, 433e-5, 462e-14
 enzyme deficiency in, 432e-4t
 genetic considerations in, 462e-14
 late-onset, 432e-4t
 prevalence of, 432e-6
 treatment of, 432e-6, 462e-14
 Ponatinib
 action and targets of, 102e-3, 102e-5t, 103e-16, 103e-17t
 adverse effects of, 103e-16, 103e-17t, 621, 692
 for CML, 691–692, 691t
 Poncet's disease, 836
 Pongola virus, 1308t
 Pons, 441e-6f, 2577–2578f
 Pontiac fever, 1015, 1016
 Pontine hemorrhage, 41e-1v
 Poor metabolizers, 38f, 40
 Popliteal artery
 aneurysm, 1647
 entrapment, 1647
 pulse, 1446f
 Popliteal (Baker's) cyst, 2222
 Population genetics, 442
 Population migration, climate change and, 151e-3–4
 Porcelain gallbladder, 2082
 POR gene mutations, 2354t, 2356t
 Porins, 930, 1004
 Pork tapeworm infection. *See* *Taenia solium* (pork tapeworm) infection
 Porphyria(s), **2521**
 acute, 367e-3, 2523t, 2525
 classification of, 2521, 2522t, 2525
 clinical features of, 2521, 2522t, 2525
 abdominal pain, 105, 2681
 autonomic dysfunction, 2642
 cutaneous, 362
 liver disease, 367e-3
 neurologic, 2681
 oral, 236
 photosensitivity, 386, 390
 cutaneous (chronic), 367e-3, 2523t, 2525–2526
 diagnosis of, 2521, 2522t, 2523t
 differential diagnosis of, 2525–2526
 erythropoietic
 clinical features of, 2521, 2522t, 2525
 congenital, 2521, 2532
 diagnosis of, 2522t
 pathophysiology of, 2522f
 protoporphyria. *See* Erythropoietic protoporphyria (EPP)
 X-linked sideroblastic anemia, 2531–2532
 global considerations in, 2521
 hepatic
 acute intermittent porphyria. *See* Acute intermittent porphyria (AIP)
 ALA-dehydratase deficient, 2521, 2526
 clinical features of, 2521, 2522t, 2526
 diagnosis of, 2522t
 hereditary coproporphyria. *See* Hereditary coproporphyria (HCP)
 pathophysiology of, 2522f
 porphyria cutanea tarda. *See* Porphyria cutanea tarda (PCT)
 unsafe drugs in, 2526, 2527–2529t
 variegate porphyria. *See* Variegate porphyria (VP)